No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Shield Therapeutics reported its strongest quarterly performance to date on Thursday, with third-quarter Accrufer prescriptions rising about 15% from the previous quarter and revenues reaching a new high, keeping the company on track to become cash flow positive by year-end.
The AIM-traded pharmaceutical group, which specialises in iron deficiency treatments, said unaudited net revenues for the three months ended 30 September rose to $13.1m from $12.8m in the second quarter and $7.2m a year earlier.
Prescription volumes increased to around 54,000 from 44,000 in the same period last year, while the average net selling price improved to $237 from $167 in the third quarter of 2024.
"I am very pleased to see Accrufer's strong performance continue into the third quarter of 2025," said chief executive Anders Lundstrom.
"The combined efforts of the Shield and Viatris Sales team along with our strategic marketing initiatives have driven continued strong performance in the third quarter, marking our strongest quarter on record with a new high in prescription volumes, net selling price, and revenues."
He added that September alone accounted for more than 40% of quarterly revenue, representing the company's highest monthly sales to date.
"This performance has reinforced our alignment with full-year performance targets enabling us to stay on track to turning cash flow positive by the end of 2025," Lundstrom said.
Shield reported cash and cash equivalents of $8.6m at the end of September, down from $10.8m three months earlier, including proceeds from a placing completed during the period.
The company said it remained confident in its financial trajectory as Accrufer continued to expand its market presence in the US.
At 1124 BST, Shield Therapeutics shares were down 0.47% at 7.36p.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.